key: cord-0737227-d0uitw8o
authors: Kamal, Faisal; Khan, Muhammad Ali; Sharma, Sachit; Imam, Zaid; Howden, Colin W.
title: Lack of consistent associations between pharmacological gastric acid suppression and adverse outcomes in patients with COVID-19: meta-analysis of observational studies.
date: 2021-02-17
journal: Gastroenterology
DOI: 10.1053/j.gastro.2021.02.028
sha: be1e8f39e5f6f8dec11a7256bd4210fcd9d4b669
doc_id: 737227
cord_uid: d0uitw8o

nan

Coronavirus disease 2019 (COVID-19), a major healthcare problem of this century, has already claimed hundreds of thousands of lives. Rigorous research is examining potential therapeutic

options. An early study reported that oral famotidine 80 mg t.i.d. was associated with improved patient-reported outcomes in non-hospitalized COVID-19 patients (1) . Since then, studies evaluating outcomes in hospitalized COVID-19 patients treated with famotidine have reported conflicting results (2) (3) (4) . It has also been suggested that proton pump inhibitors (PPIs) may be associated with increased risks of severe disease (5) and death (6) in infected patients. We conducted this meta-analysis to evaluate any association between famotidine or PPI use and outcomes in patients with COVID-19.

Methods are described in detail in the supplementary material. Briefly, we included studies that evaluated any association between famotidine or PPI use and outcomes in patients with COVID-19 and reported summary results as adjusted odds ratio (OR) or hazard ratio (HR). We assessed severity of disease and mortality among infected patients. The indicators of disease severity included endotracheal intubation, ICU admission and mortality; these are provided for each study in Supplementary Table 1 . We analyzed data using a random effects model. Heterogeneity was assessed using I 2 statistic. J o u r n a l P r e -p r o o f

We included 9 observational studies with 21,285 patients (2) (3) (4) (5) (6) (7) (8) (9) (10) . All were retrospective in design.

We found no association between famotidine use and disease severity on unadjusted analysis, RR (95% CI) 1.02 (0.58, 1.81), I 2 = 86%. Adjusted analysis including studies reporting data as OR or HR showed similar results; OR (95% CI) 1.57 (0.95, 2.59), I 2 = 0% ( Figure 1a Table 2 ).

We found no association between famotidine use and mortality; OR (95% CI) 0.79 (0.19, 3.32), The exact mechanism for this alleged benefit is unclear. However, famotidine might bind to, and inhibit, the SARS-CoV-2 protease which is necessary for breakdown of immature SARS-CoV-2 protein particles that contribute to the inflammatory response in COVID-19 patients (7).

PPIs are prescribed for a variety of indications including gastroesophageal reflux disease, risk reduction for gastric ulcer associated with NSAIDs, H. pylori infection, healing of erosive esophagitis, maintenance of healed erosive esophagitis, and Zollinger-Ellison syndrome. We found slight increases in risks of severe disease and mortality among PPI users. Of note, there was discrepancy in the disease severity analyses between studies reporting data as OR or HR. This may be because the studies reporting data as HR did not adjust data for some important variables which can affect outcomes in COVID-19 patients such as steroid or remdesivir use. In contrast, most studies reporting data as OR adjusted for these variables. There is no clear mechanism to explain why PPIs might be associated with worse outcomes in COVID-19 patients. However, suppression of gastric acid by PPIs increases intragastric pH and may result in impaired ability to destroy ingested pathogens (5).

This meta-analysis has several limitations. All of the included studies were observational and retrospective in nature, with attendant risks of measured and unmeasured confounding.

Although there was low heterogeneity in the analyses of the PPI studies, the analysis of Table 1 ) and reverse causality bias (11) . We reviewed Pubmed & MEDLINE, Embase and Web of Science Core Collection from 1/1/2020 to 12/28/20 to identify studies evaluating any association between famotidine or PPI use and outcomes in patients with COVID-19. We also reviewed the bibliographies of retrieved articles to identify any additional pertinent studies. We only included studies with hospitalized COVID-19 patients in our analysis and only assessed outcomes in patients with a diagnosis of COVID-19 who received a PPI or famotidine. We did not assess the association between PPI use and the odds of acquiring COVID-19 in the community. Our search yielded two studies (1, 2) that had evaluated an association between PPI use and the odds of acquiring COVID-19; these were excluded from our analysis. We only included published studies and did not include any unpublished data. Our search yielded four (3-6) studies that were unpublished data from medRxiv; these were excluded from our analyses.

We used the DerSimonian and Laird random effect model to analyze the data. Heterogeneity was assessed using the I 2 statistic. "We initially performed un-adjusted analysis by pooling all studies together and reported data as pooled risk ratios (RR) with 95% confidence interval (CI). We used raw data from studies to calculate RR. To analyze and report adjusted data and to explore heterogeneity, we separately pooled studies reporting data as adjusted hazard ratio (HR) or odds ratio (OR)". To assess the robustness of our results and further investigate heterogeneity, we performed sensitivity analyses by excluding J o u r n a l P r e -p r o o f each study at a time (influential analysis) (Supplementary Table 2 ). When possible, we also performed subgroup analyses based on methods of adjustment for confounders (propensity score matching vs multivariable logistic regression) and region (eastern vs western countries). 

Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors

Are Proton Pump Inhibitors Contributing to SARS-COV-2 Infection?

Associations of severe COVID-19 with polypharmacy in the REACT-SCOT case-control study

COVID-19 in patients with hepatobiliary and pancreatic diseases in East London: a single-centre cohort study

Clinical characteristics of coronavirus disease 2019 in Hainan, China. medRxiv

The influence of pH on SARS-CoV-2 infection and COVID-19 severity